Tower Research Capital (TRC)’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Tower Research Capital (TRC)'s ADPT Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Adaptive Biotechnologies (ADPT) stake by 536% in Q3 2026, buying an estimated $572K and bringing the position to 27,641 shares worth $799K. The position accounts for 0.01% of the portfolio, ranked #1221.
Tower Research Capital (TRC) first reported a position in ADPT in Q3 2019 and has held it in 27 quarters since. 334 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.
- Tower Research Capital (TRC) held 27,641 shares of Adaptive Biotechnologies worth $799K as of Q3 2026.
- Tower Research Capital (TRC) bought 23,294 Adaptive Biotechnologies shares in Q3 2026, an estimated $572K.
- Adaptive Biotechnologies made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #1221 holding.
- Tower Research Capital (TRC) first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 27 quarters since.
- 334 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.